伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例

doi:10.3760/cma.j.cn371439-20231130-00090

摘要/Abstract

摘要：

人表皮生长因子受体2（HER2）阳性乳腺癌占所有类型乳腺癌的20%左右，其侵袭性强且易转移复发；抗HER2靶向药物的研发和应用在临床上获得良好疗效，使HER2阳性转移性乳腺癌患者的总生存率得到显著提升，明显改善预后。伊尼妥单抗属于创新药，为我国首个自主研发的抗HER2单抗，现报道1例HER2阳性晚期转移性乳腺癌患者，一线应用曲妥珠单抗治疗期间发生心脏毒性，疾病进展后应用伊尼妥单抗联合卡培他滨治疗，获得长达24个月无进展生存期。

关键词: 乳腺肿瘤, 受体, erbB-2, 肿瘤转移, 心脏毒性, 伊尼妥单抗

孟繁明. 伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例[J]. 国际肿瘤学杂志, 2024, 51(8): 538-541.

图/表 4

图1

图2

图3

图4

参考文献 20

[1]	张志强, 马怡, 郑爽, 等. 实体肿瘤治疗效果评价标准的研究进展[J]. 中国临床实用医学, 2019, 10(2): 71-73. DOI: 10.3760/cma.j.issn.1673-8799.2019.02.020.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[3]	Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J]. Semin Oncol, 2020, 47(5): 259-269. DOI: 10.1053/j.seminoncol.2020.07.008. pmid: 32896428
[4]	Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792. DOI: 10.1056/NEJM200103153441101.
[5]	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274. DOI: 10.1200/JCO.2005.04.173.
[6]	Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data[J]. Ann Oncol, 2001, 12 Suppl 1: S57-S62.
[7]	Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-3752. DOI: 10.1200/JCO.2014.55.5730. pmid: 25332249
[8]	Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the North central cancer treatment group N9831 clinical trials[J]. J Clin Oncol, 2010, 28(21): 3416-3421. DOI: 10.1200/JCO.2009.23.6950. pmid: 20530275
[9]	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(10075): 1195-1205. DOI: 10.1016/S0140-6736(16)32616-2. pmid: 28215665
[10]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273-1283. DOI: 10.1056/NEJMoa0910383.
[11]	Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol, 2009, 27(34): 5685-5692. DOI: 10.1200/JCO.2008.21.4577. pmid: 19884557
[12]	Valero V, Forbes J, Pegram MD, et al. Multicenter phase Ⅲ randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer(BCIRG 007 study): two highly active therapeutic regimens[J]. J Clin Oncol, 2011, 29(2): 149-156. DOI: 10.1200/JCO.2010.28.6450.
[13]	Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. DOI: 10.1016/S1470-2045(19)30863-0. pmid: 32171426
[14]	韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J]. 中华普通外科学文献(电子版), 2021, 15(6): 453-458. DOI: 10.3877/cma.j.issn.1674-0793.2021.06.013.
[15]	边莉, 徐兵河, 邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30): 2351-2357. DOI: 10.3760/cma.j.cn112137-20200116-00105.
[16]	Wang T, Zhang P, Di LJ, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study[J]. Transl Breast Cancer Res, 2022, 3: 15. DOI: 10.21037/tbcr-21-42. pmid: 38751509
[17]	Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792. DOI: 10.1200/JCO.2005.04.1764.
[18]	Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983. DOI: 10.1200/JCO.2008.21.6531. pmid: 20038734
[19]	Xu BH, Li W, Zhang QY, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase Ⅲ, randomized, double-blind, placebo-controlled study[J]. Breast Cancer Res Treat, 2023, 197(3): 503-513. DOI: 10.1007/s10549-022-06775-1.
[20]	王晓闻, 刘培培, 吕锋华, 等. 抗HER2人源化单克隆抗体药物关键质量属性评价[J]. 中国药学杂志, 2015, 50(12): 1054-1061. DOI: 10.11669/cpj.2015.12.014.

伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭玮, 王冬慧, 王振华, 薛昭君. 晚期肿瘤患者PD-1单抗治疗后免疫相关甲状腺功能异常与生存情况的相关性[J]. 国际肿瘤学杂志, 2024, 51(8): 481-486.
[2]	赵彪, 蒲琴, 袁美芳, 马立双, 李瀚, 杨毅, 孙朝细. 基于内缘切线野的调强放疗与容积弧形调强放疗在左侧乳腺癌保乳术后放疗中的剂量学研究[J]. 国际肿瘤学杂志, 2024, 51(7): 441-447.
[3]	刘琴, 张强强, 杨继元, 胡艳. 晚期前列腺癌双侧乳腺和腋窝淋巴结转移1例[J]. 国际肿瘤学杂志, 2024, 51(7): 478-480.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[7]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[8]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[9]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[10]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[11]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[12]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[13]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[14]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[15]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.